{"id":270182,"date":"2023-11-14T04:30:00","date_gmt":"2023-11-14T09:30:00","guid":{"rendered":"https:\/\/platohealth.ai\/qa-pharmas-trial-diversity-goals-may-not-answer-health-equity-problems\/"},"modified":"2023-11-14T06:34:25","modified_gmt":"2023-11-14T11:34:25","slug":"qa-pharmas-trial-diversity-goals-may-not-answer-health-equity-problems","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/qa-pharmas-trial-diversity-goals-may-not-answer-health-equity-problems\/","title":{"rendered":"Q&A: Pharma\u2019s trial diversity goals may not answer health equity problems","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

<\/p>\n

Share this article <\/span> <\/div>\n

<!–<\/p>\n

\n

–> <\/p>\n

\n
Trial diversity and health equity are improving, but not fast enough for patients, says Access to Medicine Foundation CEO Jayasree Iyer. Credit: sulit.photos via Shutterstock. <\/figcaption><\/figure>\n<\/p><\/div>\n

Health is a fundamental human right, yet health inequity is one of the major problems across the world. Although the pharmaceutical industry is more aware of this problem due to regulatory efforts to improve clinical trial diversity and access to medicine, there is still a lot of work needed.<\/p>\n

Speaking in an exclusive interview with Clinical Trials Arena<\/em> at the sidelines of the FT Global Pharma and Biotech Summit<\/a>, Access to Medicine Foundation CEO Jayasree Iyer shared her thoughts about what role the pharma industry plays in clinical trial diversity and health equity.<\/p>\n

Urt\u0117 Fultinavi\u010di\u016bt\u0117: Over the past few years, regulatory agencies made clinical trial diversity and health equity one of their top priorities. How did it affect companies and their R&D processes?<\/strong><\/p>\n

Jayasree Iyer: If there is a real push for clinical trial diversity from a major regulator like the US Food and Drug Administration (FDA), it gets quite a lot of attention from the pharmaceutical industry. The difference is whether it is a fixed policy or a guideline. Having more inclusive clinical trials firmly embedded into the FDA requirement had a very strong ripple effect on the industry itself.<\/p>\n

It is a different discussion whether that translates into global equity. People will adhere to trial diversity within the FDA requirement, but it doesn\u2019t necessarily mean it will happen in clinical trials around the world. Every regulator is responsible for the region that they are regulating. You may do the bare minimum to respond to one rather than trying to do what is right for the whole world. This is what is happening in the industry. Companies are being more inclusive, but not in terms of global reach.<\/p>\n

\n

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.<\/p>\n